Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku to Create "Monitor System" to Have New Compounds Assessed by Outside Experts
August 20, 2007
- BUSINESS NEWS IN BRIEF
August 20, 2007
- WC6 on Alternatives and Animal Use in Life Sciences to Be Held in Tokyo
August 20, 2007
- TOPICS／ACTOS Offers Safety Profile: Takeda
August 20, 2007
- R&D NEWS IN BRIEF
August 20, 2007
- TOPICS／Avandia to Remain Available in the US: GSK
August 20, 2007
- Korosho Starts Drafting New Vision for Medical Device Industry
August 20, 2007
- SURVEY／Once-Daily Bisphosphonate Formulations Preferred to Once-Weekly Formulations
August 20, 2007
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2007
- JGPMA to Enhance Reliability of Generics: Mr Sawai
August 20, 2007
- Candidates Recommended by JMA, JPA Lose Seats in Upper House
August 20, 2007
- JMA Presents Strong Objection to the Use of Generics: Chuikyo
August 20, 2007
- LDP Must Review Its Medical Expenditure Curtailment Policy: JMA
August 20, 2007
- New NHI Pricing Systems Proposed by Industry Organizations
August 20, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 20, 2007
- FPMAJ Calls For 3-Level Premiums for Innovativeness
August 20, 2007
- SELF-MEDICATION NEWS IN BRIEF
August 20, 2007
- Fixed-Point ADR Observation Project to Be Expanded: New SD Director
August 20, 2007
- Bayer Yakuhin to Focus on Specialty Drugs
August 20, 2007
- Summary of FPMAJ's Opinions on NHI Drug Pricing System
August 20, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…